Dr. OlgaBezzubova


Munich +

Olga Bezzubova has more than 20 years of experience in obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics. Olga is co-leader of the Firm's global patent prosecution practice, leader of the Firm's European life sciences and chemistry patent prosecution group, and Munich IP practice coordinator.

Olga advises on all aspects of patent prosecution and opposition, supplementary protection certificates, patent validity, and infringement. She has experience in developing global IP strategies for established biotech companies and start-ups, as well as managing patent portfolios worldwide. Olga's unique background in physics and biology allows her to counsel clients in matters involving various aspects of cell biology, genomics, proteomics, molecular biology, food science, biopharmaceuticals, and biophysics, as well as emerging technologies at the convergence of biological and physical sciences. Olga has represented clients in highly competitive areas of RNA (ribonucleic acid) interference (RNAi) and CRISPR/Cas gene editing (clustered regularly interspaced short palindromic repeats).

Olga has authored and coauthored numerous publications in the field of molecular genetics and IP.


  • Puma Biotechnology obtains dismissal of opposition against its European patent relating to treatment for gefitinib/erlotinib-resistant cancers and cancers with T790M EGFR mutationAfter nearly 10 years of opposition and appeal proceedings, on behalf of Puma Biotechnology, Inc., Jones Day obtained dismissal of an opposition against a European patent, which broadly covers the use of irreversible inhibitors for the treatment of gefitinib/erlotinib-resistant cancers, as well as cancers with the T790M EGFR mutation.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®).
  • ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technologyJones Day is acting for ToolGen, Inc. in defense of a multi-party opposition filed at the European Patent Office against its patent rights covering application of the revolutionary CRISPR/Cas9 gene editing technology in biotechnology, medicine, and agriculture.
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day is representing CJ CheilJedang Corporation, a major Korean-based multinational company, in a patent dispute with a Japanese competitor before the courts in Germany.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
  • Speaking Engagements

    • February 7, 2017
      Brexit and the Unitary Patent System, JD Women in IP
    • November 19, 2013
      IP Strategies for Life Science Companies: The New European System, Seminar for France Biotech
    • June 4, 2013
      Divisionals in Europe: Practical Advice
    • March 25, 2013
      Europe's New Unitary Patent and Unified Patent Court: How the introduction of the Unitary Patent and Unified Patent Court will impact your existing patent portfolio